Bomai Healthcare's GEM IPO has inquired to focus on the field of high-performance interventional vascular medical devices
The Zhitong Finance App learned that on January 8, Guangdong Bomai Medical Technology Co., Ltd. (abbreviation: Bomai Medical) changed its GEM listing review status to “Inquired”. China International Finance Corporation is its sponsor and plans to raise 1.7 billion yuan.
According to the prospectus, Bomai Medical focuses on R&D, production and global sales of high-performance interventional vascular medical devices. It is a leading provider of interventional treatment solutions for complex vascular diseases with leading technology and products in the global industry, and is also a leading R&D and manufacturing enterprise in the field of domestic vascular interventional balloon catheters.
In terms of product system construction, the company has formed a complete product matrix covering multiple treatment scenarios, with more than 50 product lines. The product application areas cover key fields such as coronary intervention, peripheral intervention, neurological intervention, hemodialysis pathways and interventional accessories, including various types of general balloon catheters, functional balloon catheters, pharmaceutical balloon catheters, interventional guides and catheters, various thrombotic treatment devices, calcification devices, energy therapy devices, etc., which can fully meet the diverse clinical needs of complex vascular disease treatment interventions.
In terms of R&D and production layout, the company attaches importance to global resource integration and production capacity assurance. Currently, it has set up 5 R&D centers and laboratories around the world to continue to promote core technology iteration and innovative product development; establish 4 production bases to ensure large-scale and high-quality product supply; and at the same time build 3 international operation centers to provide efficient operation support and service guarantee for global market expansion.
In terms of market coverage, the company's products have been successfully sold in more than 100 countries and regions at home and abroad, serving tens of thousands of hospitals and medical centers around the world. With stable product performance, systematic treatment solutions and professional technical support, it has established a good brand image in the domestic and foreign vascular interventional medical device market, and has gradually built a global market layout and customer service network.
The company has long implemented the “innovation+scale+internationalization” trinity management and development strategy, and has grown into a multinational platform enterprise with rapid development in the global vascular intervention industry with important industry influence. “Helping China create originality and benefit global patients” is also the core development concept of the company's scientific and technological innovation and global industrialization. Since its establishment, the company has continued to maintain high-intensity R&D investment, built a complete and efficient R&D talent team and IPD product development system. Relying on core research carriers such as Guangdong Interventional Vascular Treatment Technology and Device Engineering Technology Research Center, Dongguan Key Laboratory for Vascular Interventional Medical Device Research and Development, and CNAS Laboratories, the company has achieved many global breakthroughs in product technology and core processes through global industry-university-research cooperation and medical innovation cooperation. As of the date of signing the prospectus, the company has listed 7 products that are the world's first or have unique innovative technology; at the same time, the company won the second prize of the 2020 Guangdong Science and Technology Progress Award as the exclusive completion unit, and 12 other products have been recognized as famous high-tech products in Guangdong Province. More than 80 domestic and international invention patents have been authorized, laying a solid foundation for continuous innovation.
As a leading company in the field of interventional vascular medical devices, Bomai Medical occupies a leading position in the market with its technical advantages and large-scale production capacity in products such as balloon catheters. According to Frost & Sullivan's data, in 2024, Bomai Medical became the fourth largest in the Chinese coronary balloon dilatation catheter market with a market share of 9.6% and the number one domestic brand; with a 4.7% market share, it became the fifth largest in the Chinese peripheral artery balloon dilatation catheter market.
On the financial side, in 2022, 2023, 2024, and January-June 2025, the company achieved operating income of approximately 207 million yuan, 335 million yuan, 460 million yuan, and 303 million yuan; for the same period, net profit was -36.614 million yuan, 25.9914 million yuan, 76.7847 million yuan, and 35.6496 million yuan, respectively.
